Evoke Pharma’s Stock Sinks on Stomach Drug’s Phase 3 Failure
Xconomy
JULY 18, 2016
Evoke’s late-stage study failed to show a significant benefit to the drug, EVK-001, versus placebo at all 41 of the sites that tested it nationally. In about one-third of the sites (13 out of 41), patients in the trial who took placebo reported an improvement in symptomatic diabetic gastroparesis.
Let's personalize your content